Thrombosis and Hemostasis Research
Thrombosis is a crucial hemostatic process for maintaining blood volume (hemostasis) following injury, yet aberrant thrombosis can trigger pathological conditions including myocardial infarction and stroke. Therefore the initiation of thrombosis is tightly controlled under physiological conditions.
Thrombosis and Hemostasis Research Products Targets
- PI 3-kinase (22)
- Cell Adhesion Molecule (21)
- Others (7)
- Cyclooxygenase (24)
- PPARγ (16)
- PPARδ (5)
- PPARα (7)
- NK2 Receptor (7)
- NK1 Receptor (15)
- NK3 Receptor (5)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Purinergic (P2Y) Receptor (31)
- Protease-Activated Receptor (23)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Phosphodiesterase (34)
Products for Thrombosis and Hemostasis Research - Page 26
- Cat.No. Product Name Information/Activity
-
BCC6828
Palmitoylethanolamide
Impulsin (AM 3112) is an active endogenous compound which can used for preventing virus infection of the respiratory tract.
-
BCC2265
WY-14643 (Pirinixic Acid)
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
-
BCC7017
MK 886
MK886 is a potent 5-lipoxygenase activating protein inhibitor (FLAP) also a non-competitive inhibitor of PPAR alpha. a potent inhibitor of leukotriene (LT) biosynthesis in intact human polymorphonuclear leukocytes with IC 50 of 2.5 nM. Block the synthessis of leukotrien intact activate leukocyte.
-
BCC2267
GW0742
GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
-
BCC2268
GW501516
GW 501516 is a PPARδ agonist with an EC50 of 1.1 nM.
-
BCC1573
FH535
FH535 is an inhibitor of Wnt/β-catenin and PPAR, with anti-tumor activities.
-
BCC7688
GSK 0660
GSK0660 is a potent antagonist of PPARβ and PPARδ, with IC50s of 155 nM for both isoforms.
-
BCC2263
GSK3787
GSK3787 is as a selective and irreversible antagonist of PPARδ with pIC50 of 6.6, with no measurable affinity for hPPARα or hPPARγ.
-
BCC7014
Ciglitazone
74772-77-3
-
BCC7786
LG 100754
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
